MMPs B00017140 2003 6
i 1 2 3 ED 3 ED 3 ED 5 5 6 9 10 12 12 13 13 14 14 15 16 16 16 ED 17 ED 17
CIEF-5 21 23 27 MMPs 28 29 31 31 31 31 34 MMPs 34 MMP 34 MMP 35 MMP 36 MMP 38 MMP 39 43 43 44 44 46 ii
50 MMP 50 MMP 50 MMP 51 51 MMP 51 MMP 51 MMP 51 51 52 56 57 64 83 iii
(Erectile Dysfunction, ED), ED 2226 CIEF ED 28.33% 40 40.20% ED 14.84% 6.58% 4.95% ED CIEF-5 ED 1
Abstract Male Erectile Function Study in 3 Chinese Cities Objective: Erectile dysfunction (ED) is one of the most common sexual disorders in aging male. It is still difficult to estimate accurately the prevalence of ED worldwide. Through this investigation, we want to determine the prevalence of Erectile dysfunction (ED) and its relative factors in China. Materials and methods: A structured questionnaire (including CIEF-5) was administered by trained interviewers. There were 2226 subjects collected from Beijing, Chongqing and Guangzhou. Results: The prevalence of ED was 28.3%(total group), and 40.2%( 40yrs group). The prevalence of mild, moderate and severe ED was 14.84%, 6.58% and 4.95%, respectively. Conclusion: Besides ageing, several medical condition such as cardiovascular disease, diabetes, hyperlipidemia were correlated with the prevalence of ED. Psychological and environmental factors such as couple relationship and living condition, are also very important to the development of ED. Lifestyle factor such as cigarette smoking, maybe another concomitant risk factor. Keywords: erectile dysfunction(ed); epidemiology; aging 2
ED ED [1] ED ED ED ED ED ED ED ED ED 1948 ED ED ED [2] 1992 NIH ED [3] ED 1994 Massachusetts Male Aging Study, MMAS [4] ED ED 3
ED ED ED 10 ED ED ED 1 1. ED / / ED Feldman et al. 1994 [4] 1290 40-70 52% 1997 [5] 1582 40 40-49 32.8% 50-59 36.4% 60-69 74.2% 70 86.3% Sato et al. 1995 [6] 3940 20-90 45-59 10% 60-64 23% 65-69 30.4% 70 44.3% 4
Pfizer Cross-National Study,1998 [7] Moreira,2001 [8] Morillo,2001 [9] 81.1% 69.8% 62.1% 39.9% 654 40-70 39.5% 2384 40 53.4% ED ED [10] [11] ED ED [12] ED ED Kinsey 1948 ED ED 20 0.1 80 75 [2] 1994 MMAS 40 70 ED 17 25 10 40 38 70 70 [4] 1995 3940 20-94 20-44 ED 2.5 45-59 10 60 69 20 70-79 33 [6] 10 22-59 967 IIEF 5
[13] 1582 40 40-49 ED 32.8 50-59 36.4 60-69 74.2 70 86.3 [5] ED ED ED ED 60 ED [14] ED ED ED 30-74 2.7-3.2% 7% 8% [15] ED ED 50-75% 292 81 20-59 ED 23 9 [16] 50 IIEF 9.6 8.1 6
21.3 9.5 [13] ED II [17] MMAS ED 3 ED 27.5-59 [4] 10 ED 50% ED 68 2 25.9 55-74 ED 7 ED 3.79 2.02 1.97 1.75 [18] ED 6 [19] MMAS 24 Cooper 12 [20] ED ED MI [13] 60 ED 59 MMAS 35 [21] ED 39 ED 15 9.6 [4] ED [14] ED 7
ED MMAS ED ED [22] ED ED [23-26] ED 45 [27] Leydig 1975 ED 1 23-53 ED 50 [28] Cerqueira 58 ED 28.6 15.1 14.3 [29] ED 82 95 CI 76-87 ED 45 CI 36-55 50 ED 63 CI 53-71 50 90 CI 84-94 [30] ED 41.5% 64.2 71.7 [31] 3 [32] ED ED [33] 50 ED 70 8
25 ED [34] ED ED 1.96 1.52 [35] MMAS ED 28 [42] ED [36-41] ED ED ED [43-45] ED [46] ED ED [47] ED 30 2 [26,48] ED [26,46,47] ED [49] LH / ATP ED [50] 9
ED [51] LHRH ED [37] ED LHRH 92 86 ED ED [52] [53] ED [38] ED ED ED ED 178 ED [54] ED 4462 ED 31-49 ED 2.2 2.0 3.7 P 0.005 [55] MMAS ED 2 24%vs14% ED [22] MMAS ED 10
ED 56 21 [4] 20% 8.5% 9.4% [4] ED 14% 41% 7.5% 21% 21% 52% [56] Mirone ED ED 2.4 2.0 1.7 ED ED [57] 50 ED 54 28 P<0.05 [58] 63 10 [59] 20 14 ED 40 10 ED [60] HDL 60mg/dl 1.55mmol/L ED 30 mg/dl 0.78mmol/L 0.3 TC 240mg/dl 6.2mmol/L 180mg/dl 4.65mmol/L ED 1.83 [60] MMAS HDL ED [4] 11
[14,61,62] ED Johannes ED 0.64 95 CI 0.44-0.91 ED Ansong [63,64] ED [65] 41 22 [66] ED 23 vs56 ED [67] ED [68] 50 [69] ED [70] ED [71] 12